| 0.5231 -0.04 (-7.1%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.71 | 1-year : | 0.83 |
| Resists | First : | 0.61 | Second : | 0.71 |
| Pivot price | 0.46 |
|||
| Supports | First : | 0.46 | Second : | 0.37 |
| MAs | MA(5) : | 0.51 |
MA(20) : | 0.47 |
| MA(100) : | 0.56 |
MA(250) : | 0.74 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 79.7 |
D(3) : | 81.1 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 1.6 | Low : | 0.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CTXR ] has closed below upper band by 21.8%. Bollinger Bands are 37.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.56 - 0.57 | 0.57 - 0.57 |
| Low: | 0.51 - 0.52 | 0.52 - 0.52 |
| Close: | 0.52 - 0.52 | 0.52 - 0.53 |
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Fri, 30 Oct 2026
Citius Pharmaceuticals, Inc. (CTXR) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Fri, 23 Oct 2026
Citius Pharmaceuticals, Inc. Estimates – NASDAQ:CTXR - TradingView
Mon, 12 Oct 2026
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences - PR Newswire
Fri, 21 Aug 2026
Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Fri, 14 Aug 2026
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Tue, 21 Jul 2026
Citius Oncology expands sales team for LYMPHIR launch - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 4.9 (%) |
| Shares Short | 5,590 (K) |
| Shares Short P.Month | 5,630 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.43 |
| Profit Margin | 0 % |
| Operating Margin | -670.3 % |
| Return on Assets (ttm) | -26.6 % |
| Return on Equity (ttm) | -81.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.2 |
| Sales Per Share | 0.25 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -0.3 |
| PEG Ratio | 0 |
| Price to Book value | 0.21 |
| Price to Sales | 2.01 |
| Price to Cash Flow | -0.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|